Rises in prescription drug sales contributed to robust third-quarter earnings growth posted by Pfizer, Lilly, Wyeth, Novartis and Schering-Plough.
Pfizer CEO Jeffrey Kindler said all aspects Pfizer’s business would be open to reductions under an ongoing company wide cost-cutting initiative.
Even small payments given by pharmaceutical companies to CME providers are not escaping the eye of federal investigators poring over their grant records as part of an ongoing inquiry.
Generic drugs considered important to the public health will now get quicker review times, FDA officials said.
Federal scientists have accused Eli Lilly of attempting to influence treatment guidelines for its blood infection treatment Xigris to boost slumping product sales.
As promised, Mark McClellan, former administrator of the centers for Medicare and Medicaid Services has joined the think tank world.
Negative articles in medical journals have a major influence over doctors’ prescribing habits, according to an article in the Journal of the American Medical Association (JAMA).
Online publisher Waterfront Media plans on going to the mat with consumer healthcare heavyweights WebMD and About Health by launching EverydayHealth.com.
Dermatology focused pharmaceutical company Stiefel Laboratories announced it has purchased prescription dermatolgical foam manufacturer Connetics Corporation for $640 million.
Federal scientists this week accused Eli Lilly of attempting to influence treatment guidelines for its blood infection treatment Xigris to boost slumping product sales.
Generic drugs considered important to the public health will now get quicker review times, FDA officials said yesterday.
Bayer pinned its failure to tell the FDA about a study regarding heart surgery drug Trasylol on an error by two unnamed individuals, as it hired outside counsel to investigate the matter.
The US Supreme Court dismissed an appeal from generic drugmaker Apotex over a patent challenge to Pfizer’s blockbuster antidepressant Zoloft.
The FDA yesterday approved Genentech’s Avastin for use in treating non-small cell lung cancer.
DTC advertising spending by pharmaceutical companies was up 9% during the first half of 2006, according to data released this week by marketing information firm TNS Media Intelligence.
A move by US Customs to relax enforcement on the importation of Rx drugs from Canada has drawn fire from the industry trade group PhRMA.
Democrats wouldn’t be in power more than four days before legislating price controls on pharmaceuticals, according to House Democratic leader Nancy Pelosi, the presumptive Speaker of the House should the Democrats win a majority of seats next month.
Altana Pharma said it would lay off about 400 workers as part of a dismantling of its US sales & marketing and research operations.
Shire Friday received tentative FDA approval to market its new attention-deficit hyperactivity disorder (ADHD) drug, lisdexamfetamine dimesylate (LDX).
Merck and Schering Plough last week won FDA approval to include new product labeling saying Vytorin is better at lowering bad cholesterol than competitor, AstraZeneca’s Crestor.
DTC advertising of prescription drugs in New Zealand could soon be a thing of the past.
Merck said it has pushed back regulatory plans for an experimental cardiovascular pill that has been hailed by some as a possible follow-on to blockbuster cholesterol drug Zocor.
The National Institutes of Health (NIH) said it will fund a clinical trial to compare two drugs used to treat advanced age-related macular degeneration (AMD): Genentech’s Lucentis and Avastin.
Pfizer entered into an agreement to acquire PowderMed, a privately held UK company specializing in the emerging science of DNA-based vaccines.
The FDA should be empowered to enforce a two-year ad ban for new drugs, according to a report by the nonprofit Institute of Medicine (IOM).
The Division of Drug Marketing, Advertising & Communication (DDMAC) has added a second DTC review group to meet soaring demand for advertising approvals, said DTC group leader Melissa Moncavage.
Lita Sands, who once headed CRM at Pfizer, has been hired by Ogilvy Healthworld as client services strategy lead in its Healthcare unit.
GlaxoSmithKline will not renew its 2007 sales engagement with contract sales firm PDI, TheStreet.com reported today.
Thomson is buying the balance of Solucient from media giant VNU, private equity firm Veronis Suhler Stevenson and healthcare provider alliance VHA.
Andrew von Eschenbach still faces hurdles in becoming permanent FDA commissioner, despite winning approval of his nomination from a Senate committee.
Germany’s Merck KGaA is buying a majority stake in Swiss rival Serono in a deal worth approximately $13.3 billion, according to published reports.
Republicans in the US House of Representatives agreed Thursday to prohibit customs agents from seizing limited amounts of prescription drugs that Americans buy in Canada and bring back into the US, The Wall Street Journal reported.
Congressional Democrats claim pharma industry profits have soared by as much as $8 billion in the first six months after the Medicare drug benefit went into effect.
Germany’s Merck KGaA is buying a majority stake in Swiss rival Serono in a deal worth approximately $13.3 billion, according to published reports.
US Rep. Henry Waxman plans to introduce Congressional legislation as early as this fall to create a framework to approve “biosimilar” or generic biologic drugs, according to published reports.
AstraZeneca will continue looking for deals to pump up its pipeline despite company expectations that most of its products, by 2010, will come from discoveries within its own labs.
Amgen CEO Kevin Sharer has been named the new chairman of PhRMA following the resignation of Peter Dolan, ousted CEO of Bristol-Myers Squibb.
Stanford University Medical Center has joined the growing cadre of academic medical centers limiting the access of sales reps to its halls and forbidding its doctors from accepting industry gifts and drug samples.
Schering-Plough is seriously considering approaching Bristol-Myers Squibb about a possible merger, the New Jersey newspaper, The Star–Ledger, reported on its Web site.
Two out of the 44 federal scientists found by the National Institutes of Health to have violated rules on outside consulting warrant further investigation for possible criminal acts, yet they remain employed by the agency.
The FDA has taken the unusual step of removing an advisory committee panel member due to a potential conflict of interest, The Wall Street Journal reported.
Authors of papers submitted to the journal Nature can agree to a new form of peer review -- having the journal post their articles online for other scientists to critique.
Pfizer and TransTech Pharma have entered into a license agreement for the development and commercialization of small and large molecule compounds under development by TransTech.
The board of Bristol-Myers Squibb named one of its directors and a former CFO for Eli Lilly as interim CEO of the company today, following a federal monitor’s recommendation to fire Peter Dolan.
The Accreditation Council for Continuing Medical Education (ACCME) has revamped its accreditation model, setting a two-year deadline for providers to change the way they plan and deliver activities.
Mark McClellan is resigning his post as head of the Centers for Medicare and Medicaid Services.
A federal judge issued a ruling Thursday allowing GlaxoSmithKline and Roche to continue marketing the osteoporosis drug Boniva, shooting down an injunction filed by market rivals to halt the drug’s promotion.
GlaxoSmithKline will pay the US government $3.4 billion—the largest tax settlement ever paid to the IRS—to end a decades-long dispute over financial dealings that ultimately allowed the British drugmaker to lower its US tax bills for nearly two decades.
AstraZeneca named Lisa Davis to head all internal and external corporate communications in the US.
Prescriptions for higher doses of Lipitor jumped 12% for the week ending Aug. 18, The Boston Globe reported.
Hill & Knowlton named GCI Group’s AnnaMaria DeSalva to head its worldwide healthcare practice.
Pfizer won the dismissal of a whistleblower lawsuit filed against the company by former marketing exec Peter Rost, accusing the firm of promoting its growth hormone Genotropin for unapproved uses.
MedImmune broke ground on a $250 million, multi-phase expansion project at its Frederick, MD, manufacturing site.
Health insurer UnitedHealth Group said it has decided to stop paying for AstraZeneca’s Nexium because equally effective proton pump inhibitor (PPI) treatments are available to patients.
Merck said the results of a 20-month company-funded investigation found that senior management acted responsibly in the development and marketing of withdrawn painkiller Vioxx, the Associated Press reported.
Nancy Lurker has been appointed senior vice president and chief marketing officer at Novartis, a new position at the drug company.
Wyeth’s $500,000 independent CME grant will enable the Medical Association of Georgia (MAG) to assess a system that delegates control over the firm’s med-ed purse strings.
Schering-Plough agreed to pay $435 million to settle charges that it lied to the government about drug prices and improperly marketed cancer drugs for uses not approved by the FDA.
Apotex must stop selling cheaper copies of the anticoagulant Plavix but doesn't have to pull product already sold, said a federal judge who granted a preliminary injunction to Plavix co-marketers Bristol-Myers Squibb (BMS) and Sanofi-Aventis.
A Norwegian court has ruled in favor of Ranbaxy Laboratories in two patent disputes involving Pfizer’s blockbuster Lipitor (atorvastatin), the world’s top selling Rx drug.
A federal judge in New Orleans ruled that a recent $51 million verdict against Merck was excessive and ordered that the damages portion of the Vioxx case be tried again.
Two-thirds of Americans strongly believe a law prohibiting the importation of prescription drugs from Canada and other countries is intended to protect pharma company profits and only 9% feel strongly that it helps protect Americans from potentially harmful drugs, according to a report on The Wall Street Journal’s Web site.
California Governor Arnold Schwarzenegger is poised to sign a bill sent to him Thursday that would impose mandatory prescription drug discounts for consumers in that state, The San Francisco Chronicle reported.
A free-trade agreement between the US and Japan could open up a lucrative market to overseas firms while conferring broad economic benefits, said Eli Lilly chief executive Sidney Taurel in a speech last Thursday in Japan.
Bill Frist, the Senate majority leader, is likely to face a fine for not meeting Tennessee’s mandatory CME requirement, the AP reported.
PhRMA quietly paid for parts of a recent multimillion-dollar ad campaign that praises lawmakers supporting the new Medicare prescription drug benefit, the Associated Press (AP) reported.
GlaxoSmithKline CEO Jean-Pierre Garnier foresees several pharmaceutical companies folding in the next few years because of increasing investments in research, he recently told German business publication Manager Magazin.
The editor of the journal Neuropsychopharmacology, Charles Nemeroff, has resigned after failing to disclose financial ties to makers of a device he wrote a favorable review of.
Biovail announced Friday that it has filed a federal lawsuit against the FDA to prevent the agency from approving a generic form of antidepressant Wellbutrin XL before ruling on a citizen petition the firm filed with the agency in December 2005.
GlaxoSmithKline announced a deal on Thursday with the privately held drug research firm ChemoCentryx to discover, develop and market novel medicines for a variety of inflammatory disorders.
Merck released results from a huge clinical trial of a possible successor to Vioxx, saying they support its bid to gain US approval for the drug. But the company also noted some cautions, including increased hypertension.
The FDA proposed a rule on Thursday to automate the process by which drug firms register themselves and list their products with the agency.
Mylan Laboratories said yesterday it plans to buy a majority stake in Indian drug ingredient company Matrix Laboratories. Mylan hopes to purchase up to 71.5% of Matrix for $736 million.
The second and final day of a federal hearing in Manhattan saw Bristol-Myers Squibb and Sanofi-Aventis back up their request for a preliminary injunction to stop generic sales of blockbuster anticoagulant Plavix.
Pharmaceutical companies’ Internet spending will increase by 25% this year to $780 million, according to a new report from market research firm eMarketer.
A federal court jury in the Eastern District of Virginia ruled unanimously that Pfizer did not infringe Synthon IP’s US patent covering a process for making amlodipine, the active ingredient in the blockbuster blood pressure drug Norvasc.
Barr Pharmaceuticals Friday resubmitted an application seeking FDA approval to sell its emergency contraceptive Plan B without a prescription.
Merck lawyers encountered two snags in Vioxx litigation last week as jurors in a federal Vioxx trial awarded the plaintiff $51 million in damages and a New Jersey state judge threw out an earlier favorable verdict for the company.
Two attention deficit hyperactivity disorder (ADHD) drugs must include new information about heart risks and psychotic behavior, the FDA said yesterday.
Karen Katen will leave Pfizer, the company said.
Barr Pharmaceuticals has formally published its tender offer for the purchase of 100% of the shares of Pliva, based in Zagreb, Croatia.
Israel-based generic drugmaker Teva Pharmaceutical yesterday began the sale of its generic version of Pfizer's Zoloft (sertraline) in the US.
Novo Nordisk won’t be able to get a court injunction immediately to stop Pfizer’s planned September launch of its inhalable insulin Exubera.
Barr Pharmaceuticals will resubmit a request to sell its morning-after contraceptive, Plan B, without a prescription, the company said after meeting with FDA officials last Tuesday.
Shire has reached a long-awaited settlement over patent litigation with Barr Pharmaceuticals over Barr’s attempt to market generic versions of Shire’s attention deficit hyperactivity disorder (ADHD) drug Adderall XR, The Wall Street Journal reported today.
Schering-Plough and Novartis will develop a once-daily inhaled combination therapy for asthma and COPD, the firms said.
GlaxoSmithKline has agreed to pay $70 million in a national settlement of civil lawsuits filed on behalf of certain individuals, health plans and insurance companies alleging the drugmaker inflated costs of several medicines, including its blockbuster nausea drug Zofran, as far back as the early 1990s.
OSI Pharmaceuticals said it would curb its research activities related to the acute macular degeneration (AMD) drug Macugen (pegaptanib) due to disappointing sales.
Chandler Chicco Agency (CCA) announced the opening of a Paris office, the most recent wholly-owned addition to CCA’s European network.
Barr Pharmaceuticals will resubmit a request to sell its morning-after contraceptive, Plan B, without a prescription, the company said after meeting with FDA officials yesterday.
Barr Pharmaceuticals and the FDA are scheduled to meet today to discuss the company’s bid to sell its emergency contraceptive Plan B without a prescription.
A federal appeals court deemed one Lipitor patent invalid, reversing a lower court’s decision, and upheld another, decreasing by a year Pfizer’s patent exclusivity on the anti-cholesterol drug.
Novo Nordisk has sued Pfizer claiming the new product Exubera violates patents on inhalable insulin.
Healthcare market research firm Manhattan Research last week named the top 10 leading Web site destinations for doctors from a new study to be released next week.
Grey Healthcare Group (GHG) has acquired Boston-based online advertising and marketing firm Catalyst.
British drugmaker GlaxoSmithKline has been reprimanded for promoting an unlicensed drug to treat the disputed condition of restless leg syndrome (RLS), The Times of London reported.
A jury in Los Angeles Wednesday cleared Merck of responsibility for the heart attack of Stewart Grossberg, a 71-year-old retired construction manager who took Vioxx for two years.
Medco Health Solutions says it expects a generic version of the blockbuster Bristol-Myers Squibb and Sanofi-Aventis blood thinner Plavix to become available in the United States this year.
Depomed yesterday announced its financial results for the quarter ended June 30, 2006.
Pfizer’s board of directors Friday selected vice chairman/general counsel Jeffrey Kindler as CEO to succeed Hank McKinnell.